Rituximab for rheumatoid arthritis: A meta-analysis and systematic review

Clinical Medicine Insights: Therapeutics

Volumn 2, Issue , 2010, Pages 749-760

  Volkmann, Elizabeth R ^a   Agrawal, Harsh ^a   Maranian, Paul ^a   Furst, Daniel E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Efficacy; Meta analaysis; Rheumatoid arthritis; Rituximab; Systematic review; Toxicity

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BUCILLAMINE; CHLOROQUINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; GOLD; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; MIZORIBINE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY;

ABDOMINAL ABSCESS; ABDOMINAL PAIN; ABSCESS; ADULT RESPIRATORY DISTRESS SYNDROME; ANAPHYLAXIS; ARTERY EMBOLISM; ARTHRALGIA; ASTHMA; ASTHMATIC STATE; ASYSTOLE; BACTERIAL ARTHRITIS; BLOOD TOXICITY; BRAIN HEMORRHAGE; BREAST CANCER; BRONCHIECTASIS; BRONCHITIS; BUERGER DISEASE; BURN INFECTION; BURSITIS; CARDIOPULMONARY INSUFFICIENCY; CARDIOVASCULAR DISEASE; CELLULITIS; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONVULSION; CORONARY ARTERY DISEASE; COUGHING; CYSTITIS; DERMATOMYCOSIS; DIABETES MELLITUS; DIARRHEA; DISEASE DURATION; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; EPIGASTRIC PAIN; EPIGLOTTITIS; EPILEPSY; ERYSIPELAS; ESOPHAGEAL ADENOCARCINOMA; ESSENTIAL TREMOR; EYE INFECTION; FATIGUE; FLU LIKE SYNDROME; FLUSHING; FOOT DISEASE; FRACTURE; GASTROENTERITIS; GASTROINTESTINAL INFECTION; GASTROINTESTINAL TOXICITY; GYNECOLOGIC DISEASE; HEART FAILURE; HEART INFARCTION; HEART TAMPONADE; HEPATITIS; HERPES SIMPLEX; HOARSENESS; HODGKIN DISEASE; HOT FLUSH; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNOTOXICITY; INFECTION; INFECTIOUS PNEUMONIA; INFLUENZA; INTERSTITIAL LUNG DISEASE; INTESTINE CARCINOMA; INTESTINE OBSTRUCTION; KIDNEY CARCINOMA; LARYNX EDEMA; LEG FRACTURE; LUNG ADENOCARCINOMA; LUNG EMBOLISM; LUNG INFECTION; LUNG TOXICITY; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; META ANALYSIS; METRORRHAGIA; MONOTHERAPY; MOUTH ULCER; MUSCULOSKELETAL DISEASE; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; OPPORTUNISTIC INFECTION; OVARY CARCINOMA; OVARY CYST; PANCREAS CANCER; PEPTIC ULCER; PROSTHESIS FAILURE; PRURITUS; PYELONEPHRITIS; RESPIRATORY FAILURE; RETREATMENT; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; SINUSITIS; SKIN CARCINOMA; SKIN TOXICITY; SPONTANEOUS ABORTION; STAPHYLOCOCCAL BACTEREMIA; STOMACH CANCER; SUPRAVENTRICULAR TACHYCARDIA; SWELLING; SYSTEMATIC REVIEW; TACHYCARDIA; THORAX PAIN; THROAT IRRITATION; THROMBOCYTOSIS; THRUSH; TOXIC HEPATITIS; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UROGENITAL TRACT DISEASE; UROSEPSIS; URTICARIA; UTERINE CERVIX CARCINOMA; VAGINA CANDIDIASIS; VOMITING; XEROSTOMIA;

EID: 77957137728     PISSN: None     EISSN: 1179559X     Source Type: Journal    
DOI: 10.4137/cmt.s5566     Document Type: Review

References (41)

1. Hochberg MC. Adult and juvenile rheumatoid arthritis: current epidemiologic concepts. Epidemiol Rev. 1981;3:27-44.
2. Grassi W, De Angelis R, Lamanna G, et al. The clinical features of rheumatoid arthritis. Eur J Radiol. 1998;27 Suppl 1:S18-24.
3. Pincus T. Long-term outcomes in rheumatoid arthritis. Br J Rheumatol. 1995;34 Suppl 2:59-73.
4. Symmons DP, Jones MA, Scott DL, et al. Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol. 1998;25:1072-7.
5. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic diseasemodifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762-84.
6. Jones G, Halbert J, Crotty M, et al. The effect of treatment on radiological progression in rheumatoid arthritis: a systematic review of randomized placebo-controlled trials. Rheumatology (Oxford). 2003;42:6-13.
7. Fries JF, Williams CA, Morfeld D, et al. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drugbased treatment strategies. Arthritis Rheum. 1996;39:616-22.
8. Finckh A, Simard JF, Duryea J, et al. The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2006; 54:54-9.
9. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50:1400-11.
10. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343:1594-602.
11. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793-806.
12. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572-81.
13. Singh JA, Christensen R, Wells GA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2009;CD007848.
14. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54:1390-400.
15. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24.
16. Prevoo ML, van 't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44-8.
17. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727-35.
18. Finckh A, Ciurea A, Brulhart L, et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis. 2010;69:387-93.
19. Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis. 010.
20. Mease PJ, Cohen S, Gaylis NB, et al. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial. J Rheumatol. 2010;37:917-27.
21. Tak PP, Rigby W, Rubbert-Roth A, et al. Inhibition of joint damage and improved clinical outcomes with a combination of rituximab and methotrexate in patients with early active rheumatoid arthritis who are naïve to MTX: A randomized active comparator placebo-controlled trial (IMAGE): ACR 2009 Abstract. Arthritis Rheum. 2009;10(10):S238.
22. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.
23. Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis. 2009;68:25-32.
24. Caporali R, Caprioli M, Bobbio-Pallavicini F, et al. DMARDS and infections in rheumatoid arthritis. Autoimmun Rev. 2008;8:139-43.
25. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimmun Rev. 2008;8:144-6.
26. Assous N, Gossec L, Dieude P, et al. Rituximab therapy in rheumatoid arthritis in daily practice. J Rheumatol. 2008;35:31-4.
27. Bingham COr, Looney RJ, Deodhar A, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum. 2010;62:64-74.
28. Bokarewa M, Lindholm C, Zendjanchi K, et al. Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy. Scand J Immunol. 2007;66:476-83.
29. Breedveld F, Agarwal S, Yin M, et al. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol. 2007;47:1119-28.
30. Brulhart L, Ciurea A, Finckh A, et al. Efficacy of B cell depletion in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor alpha agents: an open-label observational study. Ann Rheum Dis. 2006;65:1255-7.
31. Higashida J, Wun T, Schmidt S, et al. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment. J Rheumatol. 2005;32:2109-15.
32. Kavanaugh A, Rosengren S, Lee SJ, et al. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Ann Rheum Dis. 2008;67:402-8.
33. Keystone E, Fleischmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an openlabel extension analysis. Arthritis Rheum. 2007;56:3896-908.
34. McGonagle D, Tan AL, Madden J, et al. Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARDresistant rheumatoid arthritis. Rheumatology (Oxford). 2008;47:865-7.
35. Oren S, Mandelboim M, Braun-Moscovici Y, et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis. 2008;67:937-41.
36. Owczarczyk K, Hellmann M, Fliedner G, et al. Clinical outcome and B cell depletion in patients with rheumatoid arthritis receiving rituximab monotherapy in comparison with patients receiving concomitant methotrexate. Ann Rheum Dis. 2008;67:1648-9.
37. Popa C, Leandro MJ, Cambridge G, et al. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford). 2007;46:626-30.
38. Rubbert-Roth A, Tak PP, Zerbini C, et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). Rheumatology (Oxford). 2010.
39. Strangfeld A, Hierse F, Listing J, et al. RA patents treated with Rituximab: Routine care data of the german bologics register RABBIT [abstract]. Arthritis Rheum. 2008;Suppl 58:s305.
40. Teng YK, Tekstra J, Breedveld FC, et al. Rituximab fixed retreatment versus on-demand retreatment in refractory rheumatoid arthritis: comparison of two B cell depleting treatment strategies. Ann Rheum Dis. 2009;68:1075-7.
41. Thurlings RM, Vos K, Gerlag DM, et al. Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responders. Arthritis Rheum. 2008;58:3657-64.